Skip to main content
OpenTrials
Completed

NCT Number: NCT02654236

Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling

The main purpose of this study is to see whether heavy drinking will interfere with a specific pathway, called FXR signaling in the liver. The abnormality of this pathway may lead to liver injury in some patients who drink heavily.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Indiana University

Indianapolis, Indiana, 46202, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals ≥ 21 to 65 years old
  • Able to provide informed consent & negative urine pregnancy test where appropriate
  • Healthy controls must have not consumed any alcohol within 3 months prior to the screening visit
  • Heavy alcohol drinking is defined as > 40 grams per day on average in women and > 60 grams per day on average in men for a minimum of 6 months
  • Women of child bearing potential should be willing to practice contraception throughout the treatment period

Exclusion criteria

  • Active infection as evidenced by positive urine culture, blood culture, or pneumonia
  • Serum creatinine > 1.5 mg/dL
  • Known co-existing infection with hepatitis C, hepatitis B, or HIV
  • Significant systemic or major illness including COPD, CHF and renal failure that in the opinion of the Investigator would preclude the patient from participating in and completing the study.
  • Participation in another investigational drug, biologic, or medical device trial within 30 days prior to Screening
  • Previous history of jaundice or signs of liver diseases such as spider angiomata, ascites, or history of esophageal varices or hepatic encephalopathy
  • Total bilirubin > 2 mg/dl and INR > 1.5 Page 20 of 37
  • Women who are pregnant or nursing
  • Presence of any other disease or condition that is interfering with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the intestine. Patients who have undergone gastric bypass procedures will be excluded (gastric lap band is acceptable).
  • Subjects who are taking warfarin

Treatment and study plan

Placebo

Drug

1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.

10 mg Obeticholic Acid (OCA)

Drug

10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.

Primary outcomes

  1. Change in Bile Salt Metabolism (C4 )Levels to Determine Effect of FXR

    Time frame: Baseline to 28 days

  2. Change in FGF19 Levels to Determine Effect of FXR

    Time frame: Baseline to 28 days

Secondary outcomes

  1. Change in Fasting Serum Bile Salt Levels

    Time frame: Baseline to 28 days

  2. Change in Oxidative Stress Level by Measuring Malondialdehyde

    Time frame: Baseline to 28 days

  3. Change in CYP2E1 Activity by Measuring Chlorzoxazone Clearance

    Time frame: Baseline to 28 days

  4. Change in Gut Permeability Through Lactulose/Mannitol Test

    Time frame: Baseline to 28 days

    This is the measurement to quantify two non-metabolized sugar molecules-lactulose and mannitol-to determine the gut permeability

  5. Change in Bacterial Translocation Through Measures of Plasma LPS

    Time frame: Baseline to 28 days

  6. Change in Intestinal Inflammation by Measuring Stool Calprotectin

    Time frame: Baseline to 28 days

  7. Change in Activation of Innate Immunity Through Measures of TNF-alpha

    Time frame: Baseline to 28 days

  8. Change in Bacterial Translocation Through Measures of Serum sCD14

    Time frame: Baseline to 28 days

  9. Change in Activation of Innate Immunity Through Measures of IL-6

    Time frame: Baseline to 28 days

  10. Change in Activation of Innate Immunity Through Measures of IL-8

    Time frame: Baseline to 28 days

  11. Change in Activation of Innate Immunity Through Measures of IL-1

    Time frame: Baseline to 28 days

Sponsors and collaborators

Lead sponsor

Suthat Liangpunsakul

Other

Collaborators

  • Intercept Pharmaceuticals
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Registry information

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Jan 13, 2016
Registry last updated
Apr 25, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.